Summary of opinion: Inaqovi,cedazuridine,decitabine, 20/07/2023, Positive
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Inaqovi, intended for the treatment of acute myeloid leukaemia (AML). …